Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.43 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628366 | 0.81 | SCN9A (0.43) | SCN9ACRHR1 | |
| SCHEMBL14281980 | 0.80 | CRHR1 (0.56) | ABL1CRHR1RUNX1 | |
| SCHEMBL14281982 | 0.79 | CRHR1 (0.43) | ABL1SCN9ACRHR1RUNX1KCNH2 | |
| SCHEMBL14281979 | 0.76 | CRHR1 (0.56) | CRHR1 | |
| SCHEMBL14281983 | 0.74 | CRHR1 (0.44) | ABL1SCN9ACRHR1RUNX1 | |
| SCHEMBL5409786 | 0.72 | CRHR1 (0.47) | SCN9ACRHR1RUNX1 | |
| SCHEMBL24986581 | 0.72 | CRHR1 (0.47) | ABL1SCN9ACRHR1KCNH2FOXO1 | |
| SCHEMBL30185245 | 0.72 | CRHR1 (0.47) | ABL1SCN9ACRHR1KCNH2FOXO1 | |
| SCHEMBL14281978 | 0.72 | CRHR1 (0.57) | CRHR1RUNX1 | |
| SCHEMBL22366823 | 0.71 | LRRK2 (0.47) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | CRHR1, CRHR2, CRHBP | ABL1 3189/4885SCN9A 4698/4885CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.